CA Stock MarketDetailed Quotes

MDNA Medicenna Therapeutics Corp

Watchlist
  • 1.790
  • +0.070+4.07%
15min DelayMarket Closed Dec 17 16:00 ET
139.90MMarket Cap-4.71P/E (TTM)

Medicenna Therapeutics Corp Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Sep 30, 2024
(Q1)Jun 30, 2024
(FY)Mar 31, 2024
(Q4)Mar 31, 2024
(Q3)Dec 31, 2023
(Q2)Sep 30, 2023
(Q1)Jun 30, 2023
(FY)Mar 31, 2023
(Q4)Mar 31, 2023
(Q3)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-43.15%-5.61M
32.87%-2.33M
-28.47%-16.26M
-111.48%-4.85M
-10.09%-4.03M
10.95%-3.92M
-50.39%-3.47M
46.33%-12.66M
20.92%-2.29M
46.05%-3.66M
Net income from continuing operations
-11.85%-4.16M
-27.08%-3.64M
-153.44%-25.47M
-260.58%-13.9M
-336.20%-4.98M
-315.51%-3.72M
31.12%-2.86M
55.49%-10.05M
-20.27%-3.86M
76.26%-1.14M
Operating gains losses
-2.71%-986K
94.26%-72K
257.48%8.24M
647.08%10.38M
102.12%73K
68.14%-960K
-646.43%-1.25M
-4,422.31%-5.23M
--1.39M
---3.44M
Depreciation and amortization
1,000.00%11K
400.00%5K
0.00%4K
0.00%1K
0.00%1K
-50.00%1K
--1K
-89.47%4K
-87.50%1K
-90.00%1K
Remuneration paid in stock
145.69%656K
46.28%433K
-11.82%1.21M
151.03%487K
-53.24%159K
-37.91%267K
-27.27%296K
-3.11%1.37M
-15.28%194K
-20.00%340K
Other non cashItems
----
----
15.46%-984K
----
----
----
-163.64%-29K
-57.94%-1.16M
-49.50%-1.04M
-170.00%-27K
Change In working capital
-343.44%-1.13M
148.16%943K
-69.25%741K
-180.35%-822K
18.09%718K
155.23%465K
-76.56%380K
230.69%2.41M
33.03%1.02M
125.38%608K
-Change in receivables
137.42%58K
-123.02%-218K
36.31%1.68M
60.38%340K
-1.80%546K
90.50%-155K
-54.80%947K
414.03%1.23M
-56.38%212K
-18.11%556K
-Change in payables and accrued expense
-291.94%-1.19M
304.76%1.16M
-179.47%-937K
-243.28%-1.16M
230.77%172K
-21.52%620K
-19.62%-567K
181.20%1.18M
186.57%811K
101.69%52K
Cash from discontinued investing activities
Operating cash flow
-43.15%-5.61M
32.87%-2.33M
-28.47%-16.26M
-111.48%-4.85M
-10.09%-4.03M
10.95%-3.92M
-50.39%-3.47M
46.33%-12.66M
20.92%-2.29M
46.05%-3.66M
Investing cash flow
Cash flow from continuing investing activities
-2K
-31K
0
0
Net PPE purchase and sale
---2K
---31K
----
----
----
--0
--0
----
----
----
Cash from discontinued investing activities
Investing cash flow
---2K
---31K
----
----
----
--0
--0
----
----
----
Financing cash flow
Cash flow from continuing financing activities
706K
20.9M
0
0
0
0
0
538.47%24.76M
-322.35%-189K
-96.09%136K
Net common stock issuance
--0
--19.71M
--0
--0
--0
--0
--0
605.61%24.76M
--0
-101.56%-53K
Proceeds from stock option exercised by employees
--706K
--1.18M
----
----
--0
--0
--0
----
----
----
Cash from discontinued financing activities
Financing cash flow
--706K
--20.9M
--0
--0
--0
--0
--0
538.47%24.76M
-322.35%-189K
-96.09%136K
Net cash flow
Beginning cash position
20.31%35.63M
-49.45%16.98M
63.60%33.6M
-39.82%21.76M
-35.80%25.69M
53.42%29.62M
63.60%33.6M
-32.40%20.54M
54.55%36.15M
139.73%40.01M
Current changes in cash
-25.20%-4.91M
634.54%18.54M
-234.35%-16.26M
-95.36%-4.85M
-14.34%-4.03M
-120.17%-3.92M
-159.39%-3.47M
225.34%12.1M
11.81%-2.48M
-152.50%-3.52M
Effect of exchange rate changes
-4,100.00%-294K
121.25%109K
-136.95%-354K
189.61%69K
128.96%97K
-100.55%-7K
-588.57%-513K
620.65%958K
-71.11%-77K
-8,275.00%-335K
End cash Position
18.45%30.43M
20.31%35.63M
-49.45%16.98M
-49.45%16.98M
-39.82%21.76M
-35.80%25.69M
53.42%29.62M
63.60%33.6M
63.60%33.6M
54.55%36.15M
Free cash from
-43.20%-5.62M
31.98%-2.36M
-28.47%-16.26M
-111.48%-4.85M
-10.09%-4.03M
10.95%-3.92M
-50.39%-3.47M
46.33%-12.66M
20.92%-2.29M
46.05%-3.66M
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Sep 30, 2024(Q1)Jun 30, 2024(FY)Mar 31, 2024(Q4)Mar 31, 2024(Q3)Dec 31, 2023(Q2)Sep 30, 2023(Q1)Jun 30, 2023(FY)Mar 31, 2023(Q4)Mar 31, 2023(Q3)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -43.15%-5.61M32.87%-2.33M-28.47%-16.26M-111.48%-4.85M-10.09%-4.03M10.95%-3.92M-50.39%-3.47M46.33%-12.66M20.92%-2.29M46.05%-3.66M
Net income from continuing operations -11.85%-4.16M-27.08%-3.64M-153.44%-25.47M-260.58%-13.9M-336.20%-4.98M-315.51%-3.72M31.12%-2.86M55.49%-10.05M-20.27%-3.86M76.26%-1.14M
Operating gains losses -2.71%-986K94.26%-72K257.48%8.24M647.08%10.38M102.12%73K68.14%-960K-646.43%-1.25M-4,422.31%-5.23M--1.39M---3.44M
Depreciation and amortization 1,000.00%11K400.00%5K0.00%4K0.00%1K0.00%1K-50.00%1K--1K-89.47%4K-87.50%1K-90.00%1K
Remuneration paid in stock 145.69%656K46.28%433K-11.82%1.21M151.03%487K-53.24%159K-37.91%267K-27.27%296K-3.11%1.37M-15.28%194K-20.00%340K
Other non cashItems --------15.46%-984K-------------163.64%-29K-57.94%-1.16M-49.50%-1.04M-170.00%-27K
Change In working capital -343.44%-1.13M148.16%943K-69.25%741K-180.35%-822K18.09%718K155.23%465K-76.56%380K230.69%2.41M33.03%1.02M125.38%608K
-Change in receivables 137.42%58K-123.02%-218K36.31%1.68M60.38%340K-1.80%546K90.50%-155K-54.80%947K414.03%1.23M-56.38%212K-18.11%556K
-Change in payables and accrued expense -291.94%-1.19M304.76%1.16M-179.47%-937K-243.28%-1.16M230.77%172K-21.52%620K-19.62%-567K181.20%1.18M186.57%811K101.69%52K
Cash from discontinued investing activities
Operating cash flow -43.15%-5.61M32.87%-2.33M-28.47%-16.26M-111.48%-4.85M-10.09%-4.03M10.95%-3.92M-50.39%-3.47M46.33%-12.66M20.92%-2.29M46.05%-3.66M
Investing cash flow
Cash flow from continuing investing activities -2K-31K00
Net PPE purchase and sale ---2K---31K--------------0--0------------
Cash from discontinued investing activities
Investing cash flow ---2K---31K--------------0--0------------
Financing cash flow
Cash flow from continuing financing activities 706K20.9M00000538.47%24.76M-322.35%-189K-96.09%136K
Net common stock issuance --0--19.71M--0--0--0--0--0605.61%24.76M--0-101.56%-53K
Proceeds from stock option exercised by employees --706K--1.18M----------0--0--0------------
Cash from discontinued financing activities
Financing cash flow --706K--20.9M--0--0--0--0--0538.47%24.76M-322.35%-189K-96.09%136K
Net cash flow
Beginning cash position 20.31%35.63M-49.45%16.98M63.60%33.6M-39.82%21.76M-35.80%25.69M53.42%29.62M63.60%33.6M-32.40%20.54M54.55%36.15M139.73%40.01M
Current changes in cash -25.20%-4.91M634.54%18.54M-234.35%-16.26M-95.36%-4.85M-14.34%-4.03M-120.17%-3.92M-159.39%-3.47M225.34%12.1M11.81%-2.48M-152.50%-3.52M
Effect of exchange rate changes -4,100.00%-294K121.25%109K-136.95%-354K189.61%69K128.96%97K-100.55%-7K-588.57%-513K620.65%958K-71.11%-77K-8,275.00%-335K
End cash Position 18.45%30.43M20.31%35.63M-49.45%16.98M-49.45%16.98M-39.82%21.76M-35.80%25.69M53.42%29.62M63.60%33.6M63.60%33.6M54.55%36.15M
Free cash from -43.20%-5.62M31.98%-2.36M-28.47%-16.26M-111.48%-4.85M-10.09%-4.03M10.95%-3.92M-50.39%-3.47M46.33%-12.66M20.92%-2.29M46.05%-3.66M
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List
CA
Overall
Symbol
Price
% Chg

No Data